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The original suggestion that an association exists
between the ingestion of large amounts of analgesics
and the development of interstitial nephropathy was
made in 1953 [11. Since that time, many hundreds of
cases illustrating this association have been reported
from around the world [2, 3]. Presently, most
authors refer to the renal disease which develops in
patients who consume large amounts of analgesics as
analgesic "abuse" nephropathy. There are, how-
ever, in our opinion, a number of disadvantages to
the use of the word "abuse" in that designation. The
major disadvantage lies in the judgmental nature of
the word abuse. This word implies that something
about the patients' use of analgesics is consciously
inappropriate. There are, however, no data to sup-
port this implication. As we will discuss subsequent-
ly, it is not proven that only doses of analgesics
beyond those prescribed by physicians or needed for
relief of pain are associated with the development of
renal disease. We, therefore, prefer to refer to this
entity as analgesic "associated" nephropathy
(AAN); and we will do so throughout this paper.
During the first decade that followed the original
description of AAN, relatively few cases were
described from the United States. By 1975, however,
more than 100 cases [4-6] had been reported from
this country, and individual case reports have
stopped appearing. The incidence of AAN in the
USA has not yet been clearly established. It is still
debated whether AAN is an uncommon disease in
this country [7, 8], or whether it is as common here
as it is in countries like Australia which have an
established high incidence [9, 10].
In this article, we will summarize the available
information concerning the extent of the problem of
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AAN in the USA and review its clinical features and
natural history. We will conclude with some
thoughts on the pathogenesis of this disease.
Incidence of AAN in the United States
The first large series of patients with AAN from
the USA was reported in 1965 by Felner and Tuttle
[5]. Although they described 33 patients with AAN,
they did not present data concerning the frequency
or the incidence of this disease. The first study which
attempted to examine the magnitude of this problem
in the USA was published in 1975 [6]. In that study,
we reported that approximately 20% of patients with
interstitial nephropathy from the greater Philadelphia
area had ingested large quantities of mixtures of
analgesics and that this consumption appeared to be
the primary cause of their renal disease. We suggest-
ed that approximately 7% of all chronic renal disease
in the Philadelphia area, therefore, might be caused
by analgesics. Since 1975, only one other preliminary
report concerning the incidence of AAN in the USA
has appeared. DePalma, Wassanmiller, and Abuku-
rah [111 reported that at least 2%, and possibly as
many as 10%, of 153 patients on maintenance dialys-
is from California had AAN.
While the above reports suggest that AAN is a
significant problem in at least some parts of this
country, there are no hard data concerning the inci-
dence of AAN in the USA as a whole. As an initial
step in the process of gathering such information, we
recently conducted a survey of the nephrologists at
several large renal disease centers distributed across
the USA. While the subjective and preliminary
nature of this survey must be kept in mind, its results
are nonetheless interesting. Forty-two centers were
sent survey questionnaires and 30 have replied thus
far (March, 1976). A senior nephrologist at each
center was asked to estimate the number of new
cases of interstitial nephritis and the number of cases
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of definite, probable, and suspected AAN seen dur-
ing the previous 12 months. This information enabled
an estimate of the proportion of cases of interstitial
nephritis which might be etiologically related to anal-
gesic consumption.
The results of the survey are summarized in Table
1. Three hundred and twenty-eight new cases of
Table 1. Newly diagnosed cases of analgesic-associated
nephropathy (AAN) in 1976
Total cases/yr
(30 centers) Mode/center/yr
Definite AAN 101 3
Probable AAN 109 4
Suspected AAN 118 4
All cases 328 9
ANN/In 20%
a Definition of terms: Definite AAN = greater than 3 kg total or
greater than I g/day for 3 yr of index drug; probable AAN = large
intake of index drug but exact amount unknown: suspected AAN
= strong suspicion but no confirmation of large intake of index
drug; AAN/ln = cases of AAN/cases of interstitial nephropathy x
100.
AAN (suspected, probable, and definite) were seen
at the 30 centers during the year preceding the sur-
vey. Nine or more new cases were diagnosed in over
half of the centers during the 12-month period, and
half of the respondents estimated that 20% or more
of the new cases of interstitial nephritis were associ-
ated with analgesic overuse (the mean estimate was
27%).
In order to examine any geographical variation in
the perceived incidence of AAN in the USA, we
grouped the reporting centers into six geographic
areas (southeast, southcentral, southwest, northeast,
northcentral, and northwest) and compared their
responses (Fig. 1). It is clear that appreciable num-
bers of cases of AAN are seen throughout the USA.
The one potentially interesting difference in frequen-
cy is in the southeast. Here, the mean number of
cases of AAN per center was 13, and, more interest-
ingly, the estimated proportion of interstitial nephri-
tis diagnosed as AAN was 38% (as compared to 25%
or less in all other regions). The statistical signifi-
cance of this difference obviously cannot be calculat-
ed, but it clearly warrants further investigation.
Our survey, as well as earlier data, therefore,
strengthens the notion that in the USA the ingestion
of large amounts of analgesics is an important etiol-
ogical factor in a significant proportion of patients
with interstitial nephropathy (approximately 20%)
and, by extrapolation, in a significant proportion of
patients with end-stage renal disease.
Before the importance of the problem of AAN in
the USA can be fully understood, it is also necessary
to know how many people in the country consume
any given amount of analgesic drugs and the likeli-
hood that such people will develop AAN. Although
no definitive answers to either of these questions are
available, there is some information which is rele-
vant to each. For example, there are data concerning
the total consumption of various analgesic com-
pounds in the USA. The per capita consumption of
phenacetin in the USA was estimated by Gault and
associates to be 10 g for the year 1969 [4]. As shown
in Table 2, this figure is in the same range as that
reported from other countries where a high incidence
of AAN has been established.
Data on average consumption obviously does not
permit an estimate of the proportion of the popula-
tion consuming any particular amount of analgesics.
Such data can only be obtained from individual
patients' histories. In 1973, Lawson [12] summar-
iezed data concerning the patterns of analgesic use in
hospitalized patients in the Boston area over the
previous three years. Seven percent of the patients
interviewed by his group admitted to the daily use of
various analgesics in unspecified amounts. It should
be pointed out that although the 7% figure suggests
that a very large number of people in at least one
region of the USA ingest significant amounts of anal-
gesics, the actual frequency of regular use may be
significantly higher. Many observers [13, 14] have
noted that patients who ingest large quantities of
analgesics are likely either to deny their use or mini-
mize the amount taken. Furthermore, the frequency
of daily analgesic use (7%) from this study is similar
to the data generated from similar studies in coun-
tries where AAN is considered a major problem of
high incidence [15].
Most previous reports of AAN have included
patients who have consumed quantities of drugs
which exceeded some arbitrarily chosen amount of
one or more analgesic agents. Total cumulative dos-
es of 3 kg or more of the index compound [14, 16] or
daily ingestion of greater than 1 g per day for three
years or more [171 have most commonly been used.
No one has determined, however, the relative risk of
developing renal disease after any given level of
ingestion of any analgesic drug. The study by Law-
son [12] is the only one from the USA which has
attempted to address this issue. He found no signifi-
cant difference in the incidence of renal disease
between those who used analgesics daily and those
who did not. It is hazardous, however, to conclude
from his study that analgesic ingestion is etiologically
unrelated to chronic renal disease. Among the prob-
lems which mak 'it difficult to draw any definitive
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Fig. 1. Geographical variation in analgesic-associated nephropathy in USA in 1976. (Preliminary data from 30 centers.) N = mean number
of cases per center per designated region; AAN/Jn = fraction of interstitial nephntis diagnosed as analgesic-associated nephropathy; n =
number of centers responding per region. NE = northeast, NC = northcentral, NW = northwest, SE = southeast, SC = southcentral, SW
= southwest.
Table 2. Per capita consumption of phenacetin'
Country g/yr
Australia 40
Denmark 25
Switzerland 22
South Africa 12
Scotland 12
Canada 6-7
USA 10
a Gault et al [4].
conclusions from the Lawson study are: 1) the lack
of information on the specific quantities of analgesic
drugs ingested by patients admitting to daily use, 2)
the nonspecific criteria used to diagnose renal dis-
ease (e.g., a single blood urea nitrogen value) in both
analgesic users and nonusers, and 3) the fact that the
majority (66%) of analgesic users took only aspirin
(uniquely different from the pattern in patients with
AAN). Thus, in addition to neither knowing how
many people in the USA consume any given level of
analgesics nor what the likelihood of developing ren-
al disease from any level of consumption is, we also
are unable to conclude that the consumption of only
massive quantities rather than moderate amounts of
analgesics is required for the development of AAN.
Clinical features of analgesic abuse nephropathy in the
USA
Patients with AAN seen in the USA manifest basi-
cally the same clinical and laboratory features as
patients described from elsewhere. This point is
demonstrated in Table 3 where the salient features of
recently reported patients with AAN from the USA
[5, 6] are compared with those found in patients
reported from several other countries [14, 17-201.
Thus, these patients were most commonly middle-
aged females. Many had gastrointestinal complaints
and were anemic disproportionate to the degree of
azotemia. Many had hypertension which was appar-
ently a consequence of their renal disease. Similarly,
many patients had pyuria and/or symptoms of cysti-
tis, but these manifestations were often not accom-
panied by positive bacterial cultures of the urine.
Many developed progressive renal failure without
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Table 3. Spectrum of clinical features in patients with analgesic
abuse nephropathy from various series
Feature Survey of literaturea
Patients from the
United Statesb
Age 29—72 yr 32—66
Females 50—80% 72—85%
Headache 35—100% 80—85%
Anemia 60-90% 65-80%
Gastrointestinal
symptoms 40—60% 40—55%
Hypertension 15—70% 45—50%
Urinary tract
infection 30—60% 15—60%
Abnormal
urogram 85—95% 70—95%
Papillary necrosis 25—85% 25—40%
Pyuria 50—100% 70—95%
a References [14,
References [5, 61.
17—20].
ever manifesting clear evidence of a urinary
infection.
Papillary necrosis has been repeatedly described
as a major feature of AAN [17—20]. The presence of
this lesion has been documented in many autopsy
studies and has been observed radiologically [21]. It
should be stressed, however, that in many reports,
both from the USA and elsewhere, less than half of
the subjects manifest the classical radiologic features
of papillary necrosis. Furthermore, relatively few of
the reported cases have been described as having
symptomatic episodes associated with the excretion
of necrotic papillary tissue. Thus, if the diagnosis of
AAN is entertained only when clinically demonstra-
ble papillary necrosis is present, most cases will be
missed. Besides the classical clinical manifestations
of AAN summarized in Table 3, a number of addi-
tional clinical findings have been described over the
last few years in patients from the USA as well as
from other parts of the world. These include urinary
tract tumors [22, 231 and ureteral strictures [241.
Although there is continuing controversy about
the renal toxicity of both phenacetin and aspirin
when used as single agents, it appears that the inges-
tion of these two drugs in combination is the most
common finding in patients from the USA [4, 10]
with AAN. This is similar to the experience in most
other countries. It has been suggested, therefore,
that there is something especially nephrotoxic about
the ingestion of these analgesics in combination. It
could be that aspirin is the toxic drug but that only
those patients who ingest combination analgesics
ingest enough aspirin to develop AAN. Surveys of
patients who have ingested extremely large doses of
aspirin alone appear to make this an unlikely expla-
nation [25]. It is also possible that phenacetin is the
toxic drug but that its major availability to patients is
in combination form. Perhaps the most likely expla-
nation, however, is that ingestion of one of these
drugs modifies the metabolism or alters the renal
tissue response to the other drug in such a manner as
to increase its toxicity (infra vida).
Acetaminophen (N-acetyl-p-aminophenol, APAP,
paracetamol) is currently receiving increasing popu-
larity as an analgesic either alone or in combination
with aspirin in the USA. Since this substance is also
the major metabolic end product of phenacetin in
humans (more than 90% of ingested phenacetin is
converted to this compound within one hour), the
possibility that its use will also be associated with the
development of AAN needs to be investigated. Thus
far, relatively small numbers of people have ingested
large amounts of acetaminophen chronically, and
only a small number of cases of renal disease in
association with its use have been reported [19, 25,
26]. Until further proof to the contrary is available,
however, it seems that this drug should also be con-
sidered potentially related to the development of
kidney disease, at least in combination with large
amounts of aspirin. There are also experimental
observations which support this possibility (vide
infra).
The specific analgesic mixtures consumed by
patients in the USA are, of course, different from
those consumed elsewhere. Table 4 lists some of the
commonly used proprietary analgesic drugs contain-
ing either phenacetin or acetaminophen available
across the USA. There are, in addition, numerous
other analgesic combinations available on a regional
or local basis, and acetaminophen as well as aspirin
are marketed as single ingredient drugs under many
names. It is apparent from Table 4 (columns 2 and 3)
that cumulative doses of either phenacetin or ace-
taminophen, which most authors would consider
beyond that necessary to place the patient at risk for
the development of AAN, can easily be taken by
people from the USA. In fact, ingestion of analgesics
at the daily levels or for the duration shown in Table
4 are not uncommonly prescribed by physicians or
needed for the relief of pain. This is one of the
reasons we now prefer to use the term analgesic-
associated nephropathy rather than analgesic-abuse
nephropathy. It is also important to reiterate that
there is no evidence that lower cumulative doses are
unassociated with the risk of developing interstitial
nephropathy.
The natural history of analgesic abuse nephropa-
thy in other countries has been described in many
previous reports. It has been shown by Linton [27]
that discontinuation of the use of analgesics results
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Table 4. Amount of various analgesic drugs that constitute abuse, expressed in amounts of phenacetin or acetaminophena
Index drug in combinationa
Darvon
Compound
Empirin
Fiorinal
Norgesic
Sk-65
Percodan
Excedrin
Vanquish
quite often in stabilization or improvement of renal
function, while continuation of these drugs charac-
teristically results in further deterioration.
We have recently obtained followup information
on 13 of the 20 patients with AAN originally reported
in 1975 [5]. In Figure 2, the serum creatinine level in
these 13 patients at the time of initial diagnosis
(between 1969—1972) is compared to that in 1976.
Four patients are known to have stopped the use of
analgesics. In three of these, renal function
improved, while in the fourth, it was stable. The
remaining nine patients have continued their use of
analgesic drugs. In all except one of these, renal
function has deteriorated or the patient has died.
Although the ninth patient's serum creatinine level
has remained stable, she has had three episodes of
clinically apparent papillary necrosis and has devel-
oped a ureteral stricture. Our followup data, like
those of others [27], therefore, suggest that the dis-
continuation of analgesic use is associated with a
good prognosis, while continuing analgesic use is
associated with a poor one.
An important characteristic of AAN in the USA is
its underdiagnosis by physicians. Table 5 demon-
strates the two most common sources of difficulty in
making the diagnosis. The first is the failure of a
Fig. 2. Follow-up qf 13 patients with AAN from USA. t indicates patient died.
Proprietary name Phenacetin Acetaminophen
No. of tablets to
provide 1.0 g/
day
No. of years to
provide 3.0 kg at
10 tablets/day
6 5
+ 7 6
+ 8 7
+ 6
+
+
6
6
6
11
5
5
9+
+ 6
a Phenacetin and acetaminophen are used only as indices of amount of consumption, not necessarily to imply that they are the primary
nephrotoxin.
Dalysis
10
I
Ea
a(I,
1969-12 1976
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Table 5. Difficulties in diagnosing AAN
Diagnosis made by
Patients
initially
denying
use
Patients
initially
admitting
use
Primary physician
Consulting nephrologist
0
7
5
8
patient's primary physician to elicit the history of
analgesic use even from a patient who is willing to
report the quantity of analgesics consumed. This
failure may have many causes but probably is related
to a lack of awareness by the physician of the inci-
dence and frequency of AAN. The second difficulty
in diagnosis is the denial by many patients of either
the use or the extent of use of analgesic drugs. In
some patients, we have only been able to obtain an
accurate analgesic use history from their family,
friends, or pharmacist. There are undoubtedly many
reasons why patients deny or minimize their use of
analgesics. We feel, however, that some of these
may relate to the feeling that such use is considered
inappropriate. This feeling may be unintentionally
supported by the use of the judgmental word
"abuse" in the term analgesic abuse nephropathy.
This is one of the reasons we now prefer the term
analgesic-associated nephropathy.
When a patient who denies or minimizes his/her
analgesic use is cared for by a physician who does
not pursue the history vigorously, the diagnosis is
predictably missed. In these instances, the etiology
of the renal disease is assumed to be "unknown" or
secondary to recurrent urinary tract infections or to
mild essential hypertension. Only if the possibility
that every patient with interstitial nephritis may have
AAN is considered and only if the history of analge-
sic use is aggressively pursued in all patients with
chronic renal disease will most cases of AAN be
correctly diagnosed. It would seem that more inten-
sive efforts to educate practicing physicians along
these lines are needed before the true incidence of
AAN in the USA will be known.
Pathogenesis
Most of the experimental work that has examined
the pathogenesis of AAN has been reviewed else-
where in this symposium. There are still unresolved
controversies concerning: the exact drugs which
cause AAN, the ability of these drugs to produce
renal damage alone as opposed to combinations of
drugs, the quantity of these drugs which is necessary
to cause clinical significant renal disease, and mecha-
nism by which they cause renal damage.
In humans, as well as in animals, it has been
demonstrated that the histopathology of AAN is that
of an interstitial nephropathy which appears to be
secondary to a process which begins in the deeper
zones of the medulla [141. The earliest histologic
change which has been consistently demonstrated is
papillary necrosis [28]. It has not been established,
however, whether the initiating event in the develop-
ment of papillary necrosis is vascular damage [2] or
direct damage to the tubule or interstitial cells [291.
While the descriptive histopathology of AAN is
fairly well established, the pathogenesis is not. Natu-
rally, much of the experimental work concerning the
nephrotoxicity of analgesics has been done in ani-
mals. All of this work suffers from a number of
serious shortcomings. Species differences exist in
regard to both the metabolism and the toxic manifes-
tations of various analgesics. In most studies, the
period of drug exposure in animals has not been long
either in absolute time or in proportion to the ani-
mal's life span. On the other hand, the daily doses of
analgesics utilized have often been extremely high in
relation to the doses consumed by patients. Despite
these problems, observations in animals suggest that
analgesics can cause renal damage of the type seen in
humans.
Phenacetin or acetaminophen can produce papil-
lary necrosis in rats but does so only when given in
very large doses and then only in a small percentage
of exposed animals [30—32]. Aspirin alone can also
cause papillary necrosis in rats after the ingestion of
relatively high doses [33]. The combination of phen-
acetin and aspirin given either in high doses for a
short period of time or in lower doses (comparable to
those taken by humans) over a relatively long period
produces a relatively high incidence of papillary
necrosis [33—35]. In addition, in one study, acetami-
nophen and aspirin produced papillary necrosis in
22% of rats [33]. The addition of dehydration to
any of the drug regimens outlined above has been
shown to increase the frequency with which papil-
lary necrosis develps [34, 351. Thus, while in suffi-
ciently high doses, aspirin alone or phenacetin alone
(acetaminophen alone has not been studied in a com-
parable way) can produce papillary necrosis and ren-
al medullary damage, there is evidence to suggest
that the combination of aspirin and phenacetin (and
perhaps aspirin and acetaminophen) produces renal
damage more consistently than either agent alone. A
controlled chronic study in rats done in our labora-
tory demonstrated, for instance, that the combina-
tion of phenacetin and aspirin produced renal papil-
lary changes more commonly than did either drug
given alone in comparable doses [36].
The evidence thus far available suggests that the
nephrotoxic effects of analgesics are due to direct
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toxic effects of one or more of the metabolites of
these agents. It has been demonstrated that after the
ingestion of either phenacetin or acetaminophen by
dogs and rats, acetaminophen is concentrated in the
kidney and that a gradient is developed with the
highest concentrations in the papila [371. Within the
papillae, acetaminophen has been shown by Duggin
and Mudge [381 to reach higher concentrations in the
tubular cells than in the interstitial or intratubular
fluid. Aspirin also has been shown to concentrate in
the kidney, although there is conflicting evidence
concerning the existence of a medullary gradient [37,
39, 40]. Interestingly, dehydration increases the ren-
al concentration of both aspirin and acetaminophen
[37] and increases the intracellular to extracellular
concentration gradient of acetaminophen [381. These
animal studies thus suggest that after the ingestion of
these analgesics, the various metabolites accumulate
in the areas of the kidney where the earliest levels of
AAN develop.
The exact mechanism by which metabolites of the
various analgesics produce their damage is not
known. A hypothesis which relates the earliest sites
of damage caused by analgesics to the location of
their metabolites and to one or more of the known
toxic effects of these metabolites can be formulated,
however. One potential toxic effect of acetamino-
phen is oxidative damage. Red blood cells which are
deficient in glucose-6 phosphate dehydrogenase
(G6PD), and therefore deficient in NADPH, are sus-
ceptible to oxidative breakdown by phenacetin and!
or acetaminophen. The cells of the kidney normally
defend against oxidative damage through the mainte-
nance of a certain concentration of intracellular
reducing agents. The primary mechanism by which
this concentration is maintained is through the activi-
ty of the hexose monophosphase shunt. Sufficiently
high intracellular levels of acetaminophen (or any
other oxidizing agent), however, could overwhelm
this protective mechanism. Mudge has demonstrated
that both cortical and medullary cells in the kidneys
of rats and mice that have been given acetaminophen
are depleted of glutathione and presumably of other
reducing agents [9]. This suggests that the cells'
ability to defend against oxidative damage has been
exhausted. The exact mechanism by which acetami-
nophen or its metabolites causes oxidative damage
after depleting these cellular defenses is not yet
clearly established. Mudge has suggested [9] that
this occurs as a result of covalent binding of the toxic
metabolites to sulthydryl groups of tissue proteins
with subsequent tissue necrosis.
While the mechanism of damage postulated above
would explain the development of renal damage after
sufficiently high doses of acetaminophen alone, it
also could explain the development of this damage
by lower doses of either of these agents in combina-
tion with aspirin. One of the toxic effects of aspirin
or its metabolic products is inhibition of the hexose
monophosphate shunt in red blood cells [41]. Inhibi-
tion of this pathway, in tum, compromises the ability
of cells to generate sufficient reducing agents to
defend against oxidative damage. We have demon-
strated, in fact, that in the kidney the hexose mono-
phosphate shunt is inhibited by aspirin [36]. Thus, in
the presence of renal accumulation of aspirin, ace-
taminophen may cause oxidative damage at lower
concentrations than would be necessary if salicylate
were not present. Furthermore, since it is quite likely
that other agents have the ability to induce oxidative
damage to the cells of the kidney, it is not unlikely
that the ingestion of very high doses of aspirin alone
could result in renal damage in some patients. While
this hypothesis fits with the clinical and experimental
data available, it must be emphasized that there is
little direct proof that it is correct.
Conclusion
AAN certainly occurs in the USA. There appears
to be increasing evidence, in fact, that the incidence
and frequency of AAN in the USA is similar to that
in other parts of the world. If this is indeed the case,
then AAN is an important cause of both interstitial
nephropathy and of chronic renal disease in this
country.
Patients with AAN from the USA present with the
same clinical features as patients in other parts of the
world and share the same natural history. It may be
that the previously suspected low incidence of this
disease in the USA really reflected an underdiagnosis
by physicians.
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